179 related articles for article (PubMed ID: 19470631)
1. Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia.
Mauras N; Bishop K; Merinbaum D; Emeribe U; Agbo F; Lowe E
J Clin Endocrinol Metab; 2009 Aug; 94(8):2975-8. PubMed ID: 19470631
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial.
Plourde PV; Reiter EO; Jou HC; Desrochers PE; Rubin SD; Bercu BB; Diamond FB; Backeljauw PF
J Clin Endocrinol Metab; 2004 Sep; 89(9):4428-33. PubMed ID: 15356042
[TBL] [Abstract][Full Text] [Related]
3. Treatment of pubertal gynecomastia with the specific aromatase inhibitor anastrozole.
Riepe FG; Baus I; Wiest S; Krone N; Sippell WG; Partsch CJ
Horm Res; 2004; 62(3):113-8. PubMed ID: 15273427
[TBL] [Abstract][Full Text] [Related]
4. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
Boccardo F; Rubagotti A; Conti G; Potenzoni D; Manganelli A; Del Monaco D
Cancer Chemother Pharmacol; 2005 Oct; 56(4):415-20. PubMed ID: 15838655
[TBL] [Abstract][Full Text] [Related]
5. Letrozole vs anastrozole for height augmentation in short pubertal males: first year data.
Neely EK; Kumar RB; Payne SL; Ranadive SA; Suchet DI
J Clin Endocrinol Metab; 2014 Nov; 99(11):4086-93. PubMed ID: 25137428
[TBL] [Abstract][Full Text] [Related]
6. Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.
Hubalek M; Oberguggenberger A; Beer B; Meraner V; Sztankay M; Oberacher H; Schubert B; Wildt L; Seeber B; Giesinger J; Kemmler G; Holzner B; Sperner-Unterweger B
Clin Breast Cancer; 2014 Aug; 14(4):291-6. PubMed ID: 24468298
[TBL] [Abstract][Full Text] [Related]
7. Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years.
Mauras N; Gonzalez de Pijem L; Hsiang HY; Desrosiers P; Rapaport R; Schwartz ID; Klein KO; Singh RJ; Miyamoto A; Bishop K
J Clin Endocrinol Metab; 2008 Mar; 93(3):823-31. PubMed ID: 18165285
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of the pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose anastrozole in healthy, premenopausal female volunteers.
Tredway DR; Buraglio M; Hemsey G; Denton G
Fertil Steril; 2004 Dec; 82(6):1587-93. PubMed ID: 15589864
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial.
Schultze-Mosgau MH; Waellnitz K; Nave R; Klein S; Kraetzschmar J; Rautenberg T; Schmitz H; Rohde B
Hum Reprod; 2016 Aug; 31(8):1713-22. PubMed ID: 27390369
[TBL] [Abstract][Full Text] [Related]
10. Use of aromatase inhibitors in large cell calcifying sertoli cell tumors: effects on gynecomastia, growth velocity, and bone age.
Crocker MK; Gourgari E; Lodish M; Stratakis CA
J Clin Endocrinol Metab; 2014 Dec; 99(12):E2673-80. PubMed ID: 25226294
[TBL] [Abstract][Full Text] [Related]
11. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
Buzdar AU; Jones SE; Vogel CL; Wolter J; Plourde P; Webster A
Cancer; 1997 Feb; 79(4):730-9. PubMed ID: 9024711
[TBL] [Abstract][Full Text] [Related]
12. Gynaecomastia: the anastrozole paradox.
Bedognetti D; Rubagotti A; Zoppoli G; Boccardo F
J Pediatr Endocrinol Metab; 2010; 23(1-2):205-6. PubMed ID: 20432826
[No Abstract] [Full Text] [Related]
13. Arimidex: a potent and selective fourth-generation aromatase inhibitor.
Plourde PV; Dyroff M; Dukes M
Breast Cancer Res Treat; 1994; 30(1):103-11. PubMed ID: 7949201
[TBL] [Abstract][Full Text] [Related]
14. Prepubertal gynecomastia in two monozygotic twins with Peutz-Jeghers syndrome: two years' treatment with anastrozole and genetic study.
Grandone A; del Giudice EM; Cirillo G; Santarpia M; Coppola F; Perrone L
Horm Res Paediatr; 2011; 75(5):374-9. PubMed ID: 21335955
[TBL] [Abstract][Full Text] [Related]
15. Prepubertal gynecomastia in Peutz-Jeghers syndrome: incomplete penetrance in a familial case and management with an aromatase inhibitor.
Lefevre H; Bouvattier C; Lahlou N; Adamsbaum C; Bougnères P; Carel JC
Eur J Endocrinol; 2006 Feb; 154(2):221-7. PubMed ID: 16452534
[TBL] [Abstract][Full Text] [Related]
16. Dominant transmission of prepubertal gynecomastia due to serum estrone excess: hormonal, biochemical, and genetic analysis in a large kindred.
Binder G; Iliev DI; Dufke A; Wabitsch M; Schweizer R; Ranke MB; Schmidt M
J Clin Endocrinol Metab; 2005 Jan; 90(1):484-92. PubMed ID: 15483104
[TBL] [Abstract][Full Text] [Related]
17. Estrogen suppression in males: metabolic effects.
Mauras N; O'Brien KO; Klein KO; Hayes V
J Clin Endocrinol Metab; 2000 Jul; 85(7):2370-7. PubMed ID: 10902781
[TBL] [Abstract][Full Text] [Related]
18. Anastrozole.
Kelly CM; Buzdar AU
Expert Opin Drug Saf; 2010 Nov; 9(6):995-1003. PubMed ID: 20923259
[TBL] [Abstract][Full Text] [Related]
19. Characterization of anastrozole effects, delivered by an intravaginal ring in cynomolgus monkeys.
Rotgeri A; Korolainen H; Sundholm O; Schmitz H; Fuhrmann U; Prelle K; Sacher F
Hum Reprod; 2015 Feb; 30(2):308-14. PubMed ID: 25432919
[TBL] [Abstract][Full Text] [Related]
20. An open label 12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys.
Mauras N; Welch S; Rini A; Klein KO
J Pediatr Endocrinol Metab; 2004 Dec; 17(12):1597-606. PubMed ID: 15645693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
